A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of
JNJ-40346527 200 mg/day (100 mg twice daily) for 12 weeks, compared with placebo, in patients
with active rheumatoid arthritis (RA) despite disease-modifying antirheumatic drug (DMARD)
therapy.